Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals

Sino Biopharmaceutical, Shanghai Pharmaceuticals, CSPC Pharmaceutical, WuXi AppTec, WuXi Biologics, Shanghai Pharmaceuticals

🏢 Sino Biopharmaceutical (1177 HK) – Leading the Charge with Innovative Drug Development

Recommendation: BUY
Target Price: Not specified
Stop Loss: Not specified
Date of Recommendation: 30th August 2024
Broker: OCBC Investment Research

Investment Thesis: Sino Biopharmaceutical remains a top pick in the Chinese healthcare sector due to its strong focus on innovative drug development and a robust product pipeline. The company’s 1H24 results underscored its resilience, with significant contributions from its innovative drugs segment, which continues to drive revenue growth.

• Strong 1H24 Performance: Sino Biopharmaceutical reported a year-on-year (YoY) revenue growth of 11.1%, reaching CNY15.9 billion, with net profit growing by 14.1% YoY to CNY1.5 billion. The growth was primarily driven by the strong performance of its innovative drugs, which saw a 14.8% YoY increase, contributing CNY6.1 billion to sales.
• Innovative Drug Pipeline: The company’s innovative drug portfolio is expanding rapidly, with the approval of three new products in 1H24, including its PD-L1 drug. Sino Biopharmaceutical expects to launch 3-5 new innovative products per year between 2025 and 2026, positioning it as a leader in the innovative drug space.
• Long-Term Growth Outlook: Management anticipates double-digit sales growth in the coming years, supported by high-teens growth in its innovative drugs and biosimilars segments. The company’s strong R&D capabilities and robust product pipeline provide a solid foundation for sustained growth.

Valuation and Financials:
While the report does not specify a target price, Sino Biopharmaceutical’s strong financial performance and strategic focus on innovation suggest significant upside potential. The company’s earnings visibility and resilient growth make it a compelling investment opportunity.

Share Price Catalysts:

• Continued expansion of the innovative drug pipeline.
• Successful launch of new products driving revenue growth.
• Supportive government policies for innovative drug development.

🏥 Shanghai Pharmaceuticals (2607 HK/601607 CH) – A Strategic Play on SOE Reform

Recommendation: BUY
Target Price: Not specified
Stop Loss: Not specified
Date of Recommendation: 30th August 2024
Broker: OCBC Investment Research

Investment Thesis: Shanghai Pharmaceuticals is well-positioned to benefit from ongoing state-owned enterprise (SOE) reforms, making it a strategic play in the Chinese healthcare sector. The company’s strong distribution network, coupled with its aggressive cost-saving initiatives, supports a positive outlook.

• Strong 1H24 Financials: Shanghai Pharmaceuticals reported a 5.1% YoY increase in revenue to CNY139.4 billion and a 12.7% YoY growth in net profit to CNY2.9 billion. The company’s distribution revenue grew by 7.5% YoY, outperforming its peers, driven by the integration of its North and South distribution networks.
• Focus on R&D and Innovation: The company is increasing its focus on research and development (R&D) and innovation, which is expected to drive long-term growth. Management’s commitment to maintaining stable margins and returns on equity (ROE) further enhances its investment appeal.
• Dividend Payout: Shanghai Pharmaceuticals has a dividend payout ratio of 40%, the highest among SOE distributors, reflecting its commitment to returning value to shareholders.

Valuation and Financials:
Shanghai Pharmaceuticals’ valuation is supported by its strong earnings growth and strategic initiatives. The company’s focus on innovation, cost efficiency, and stable returns positions it well for future growth.

Share Price Catalysts:

• Successful integration of distribution networks driving efficiency.
• Increased focus on innovation and R&D.
• Positive impact from SOE reforms.

💊 CSPC Pharmaceutical (1093 HK) – A Long-Term Growth Story with Near-Term Challenges

Recommendation: HOLD
Target Price: Not specified
Stop Loss: Not specified
Date of Recommendation: 30th August 2024
Broker: OCBC Investment Research

Investment Thesis: CSPC Pharmaceutical remains a key player in the Chinese healthcare sector, but it faces near-term challenges due to the impact of volume-based procurement (VBP) and weaker-than-expected 1H24 results. Despite these challenges, CSPC’s long-term growth prospects remain intact, supported by its innovative drug pipeline.

• 1H24 Performance: CSPC’s revenue grew by 1.3% YoY, and net profit increased by 1.8% YoY, but both metrics missed market expectations. The miss was largely due to lower sales in oncology and cardiovascular drugs, impacted by multi-region VBP, and weaker sales of new products due to less productive marketing activities.
• Impact of VBP: The ongoing impact of VBP on CSPC’s sales could persist longer than expected, affecting near-term earnings. However, CSPC’s wide range of innovative drugs in its pipeline provides a strong foundation for long-term revenue growth.

Valuation and Financials:
CSPC Pharmaceutical’s current valuation reflects its near-term challenges. While the company’s long-term outlook remains positive, driven by its innovative drug pipeline, investors may need to be patient as the impact of VBP on sales continues to play out.

Share Price Catalysts:

• Recovery in sales of oncology and cardiovascular drugs.
• Successful commercialization of new products.
• Easing of VBP impact on sales.

🔬 WuXi AppTec (2359 HK/603259 CH) – Navigating Uncertainty with Strong Order Backlog

Recommendation: BUY
Target Price: Not specified
Stop Loss: Not specified
Date of Recommendation: 30th August 2024
Broker: OCBC Investment Research

Investment Thesis: WuXi AppTec, a leading contract research organization (CRO), continues to navigate geopolitical uncertainties, particularly the US Biosecure Act, with a strong order backlog and resilient financial performance. The company remains a key player in the global healthcare supply chain.

• 1H24 Financial Performance: WuXi AppTec reported 1H24 revenue of CNY17.2 billion, down 8.6% YoY, with adjusted net profit declining by 14.2% YoY to CNY4.4 billion. Despite these declines, the company maintained its full-year revenue guidance, supported by a healthy order backlog.
• Impact of US Biosecure Act: The impending US Biosecure Act poses uncertainty, particularly for WuXi AppTec’s US-based operations. However, the company’s geographic diversification and strong client relationships have mitigated some of the risks.
• Order Backlog: WuXi AppTec’s order backlog remains strong, with management expecting 80% of new orders to convert into revenue within the next 18 months. This provides a buffer against potential disruptions from the US Biosecure Act.

Valuation and Financials:
WuXi AppTec’s valuation reflects the uncertainties posed by geopolitical risks. However, the company’s strong order backlog and diversified client base support its long-term growth prospects.

Share Price Catalysts:

• Successful navigation of geopolitical risks.
• Conversion of order backlog into revenue.
• Positive developments in US-China relations.

🔬 WuXi Biologics (2269 HK) – Resilient Growth Despite Geopolitical Challenges

Recommendation: BUY
Target Price: Not specified
Stop Loss: Not specified
Date of Recommendation: 30th August 2024
Broker: OCBC Investment Research

Investment Thesis: WuXi Biologics continues to deliver resilient growth, supported by a strong product pipeline and international expansion, despite challenges posed by the US Biosecure Act. The company remains a leader in the biopharmaceutical industry with a focus on innovation.

• 1H24 Financial Performance: WuXi Biologics reported 1H24 revenue growth of 1.0% YoY to CNY8.6 billion, with adjusted net profit declining by 13% YoY to CNY2.5 billion. Despite the challenges, management maintained its full-year revenue growth guidance, anticipating strong growth in 2H24.
• Geopolitical Risks: Similar to WuXi AppTec, WuXi Biologics faces uncertainty due to the US Biosecure Act. However, the company’s focus on innovation and long-term contracts with multinational clients provide a buffer against these risks.
• Product Pipeline and Expansion: WuXi Biologics continues to expand its product pipeline and increase capacity utilization, supporting its long-term growth prospects. The company’s milestone fees from drug discovery services are expected to contribute positively to earnings in 2H24.

Valuation and Financials:
WuXi Biologics’ valuation reflects its strong growth potential, despite the geopolitical challenges. The company’s focus on innovation and long-term client relationships support a positive outlook.

Share Price Catalysts:

• Successful navigation of geopolitical risks.
• Growth in capacity utilization and product pipeline.
• Positive developments in US-China relations.

  Thank you